Mann Eye Institute launches personalized PRP eye drop for chronic dry eye

By AI, Created 11:45 AM UTC, May 20, 2026, /AGP/ – Mann Eye Institute has introduced MYE Drop, a preservative-free platelet-rich plasma treatment now available in Houston and Austin for patients with chronic dry eye. The therapy is designed to help people who have not responded to artificial tears or prescription drops and may benefit patients with more complex ocular surface disease.

Why it matters: - Chronic dry eye affects more than 100 million people worldwide, and conventional treatments often do not fully relieve symptoms. - MYE Drop adds a biologic, patient-specific option for people who want a natural, drug-free treatment or have not improved with standard eye drops. - The treatment may be especially relevant for patients with moderate to severe dry eye and autoimmune-related eye disease.

What happened: - Mann Eye Institute introduced MYE Drop, a personalized platelet-rich plasma therapy for chronic dry eye. - The treatment is now available at Mann Eye Institute’s Ocular Surface Treatment Centers in Houston and Austin. - Mann Eye Institute operates 16 locations across the Houston and Austin areas. - The institute said patients can learn more or schedule a consultation at more information.

The details: - MYE Drop is made from a patient’s own blood and is preservative-free. - The process concentrates platelets, growth factors, proteins and vitamins, then delivers them directly to the eye’s surface. - The treatment is positioned as an alternative for patients who have not found relief through artificial tears or prescription drops. - Dr. Mike Mann said MYE Drop gives clinicians a new option for patients whose dry eye has not responded to traditional therapies. - The institute said MYE Drop may fit patients with post-surgical dry eye, Sjögren’s syndrome, lupus, thyroid disease, persistent epithelial defects, recurrent corneal erosions and sensitivity to conventional eye drops. - Clinical evidence supports PRP eye drops for moderate to severe ocular surface disease, limbal cell deficiency, cicatricial conjunctivitis, dormant corneal ulcers and reducing recurrent corneal erosions in epithelial basement membrane dystrophy. - Treatment starts with a blood draw in the office, followed by centrifugation that separates the platelet-rich plasma layer at four times the platelet concentration of whole blood. - The drops are transferred into sterile amber glass bottles in a controlled environment. - Patients leave with 12 to 14 individually labeled bottles, which equals a three-month supply, in a personalized MYE Drop box. - The appointment takes about 45 minutes. - Patients use 1 drop four times daily in the affected eye or eyes. - The current vial is refrigerated between uses, while the remaining vials are frozen until needed. - A follow-up visit is scheduled about four to eight weeks after the first appointment. - Mann Eye Institute said MYE Drop preserves and concentrates platelets, unlike autologous serum drops, which remove platelets during preparation.

Between the lines: - Mann Eye Institute is betting that a more personalized biologic treatment can stand out in a dry-eye market where many patients continue to struggle after trying standard therapies. - The pitch combines clinical positioning and convenience: an in-office process, a multi-month supply and storage instructions designed to make ongoing use easier. - The emphasis on the patient’s own blood and preservative-free formulation appears aimed at patients concerned about irritation or long-term drop use.

What’s next: - Patients can now access MYE Drop at Mann Eye Institute’s Houston and Austin ocular surface centers. - Mann Eye Institute expects follow-up visits to track response after the initial treatment. - The company is directing patients to its website for consultation requests and additional information.

The bottom line: - MYE Drop gives Mann Eye Institute a new biologic option for chronic dry eye patients who have not gotten enough relief from conventional care.